The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Abeona Therapeutics Inc | COM | 00289Y107 | 16,849 | 2,359,767 | SH | SOLE | 2,359,767 | 0 | 0 | ||
| Aldeyra Therapeutics Inc | COM | 01438T106 | 4,018 | 484,096 | SH | SOLE | 484,096 | 0 | 0 | ||
| Anavex Life Sciences Corp | COM NEW | 032797300 | 1,130 | 724,205 | SH | SOLE | 724,205 | 0 | 0 | ||
| Biohaven Pharmactl Hldg Co L | COM | G11196105 | 27,728 | 749,815 | SH | SOLE | 749,815 | 0 | 0 | ||
| Chromadex Corp | COM NEW | 171077407 | 154 | 45,019 | SH | SOLE | 45,019 | 0 | 0 | ||
| Corbus Pharmaceuticals HLDGS | COM | 21833P103 | 23,727 | 4,062,791 | SH | SOLE | 4,062,791 | 0 | 0 | ||
| Eiger Biopharmaceuticals Inc | COM | 28249U105 | 764 | 75,238 | SH | SOLE | 75,238 | 0 | 0 | ||
| Electrocore Inc | COM | 28531P103 | 2,484 | 396,825 | SH | SOLE | 396,825 | 0 | 0 | ||
| Entera Bio Ltd | SHS | M40527109 | 1,450 | 475,540 | SH | SOLE | 475,540 | 0 | 0 | ||
| Evoke Pharma Inc | COM | 30049G104 | 682 | 275,000 | SH | SOLE | 275,000 | 0 | 0 | ||
| Galmed Pharmaceuticals Ltd | SHS | M47238106 | 1,434 | 210,000 | SH | SOLE | 210,000 | 0 | 0 | ||
| Krystal Biotech Inc | COM | 501147102 | 6,234 | 300,000 | SH | SOLE | 300,000 | 0 | 0 | ||
| Lipocine Inc New | COM | 53630X104 | 65 | 50,000 | SH | SOLE | 50,000 | 0 | 0 | ||
| Molecular Templates | COM | 608550109 | 460 | 113,905 | SH | SOLE | 113,905 | 0 | 0 | ||
| Soligenix Inc. | COM | 834223307 | 721 | 837,800 | SH | SOLE | 837,800 | 0 | 0 | ||